March 5, 2014
IDIBAPS creates Transplant Biotech, a spin off company for innovation in medical devices related to organ transplantation, metabolic, liver and kidney diseases
On Monday 3th of March it was celebrated the establishment of Transplant Biotech S.L., the first spin -off 100 % IDIBAPS led by IDIBAPS's researchers: Dr. Carmen Peralta, an expert in therapeutic strategies in ischemia - reperfusion, with Dr. Anna Novials, expert in diabetes, and Dr. Jordi Gracia, a specialist in vascular biology. The participation of Dr. Peralta in BioEmprenedorXXI program, an initiative of Biocat, la Caixa and Barcelona Activa, with the goal of supporting entrepreneurship in the field of biotechnology and biomedicine, has enabled the translation of a project research in a business plan. Thanks to Dr. Josep Lluís Falco, project tutor assigned by the program, the research team was able to develop a business plan for innovation in medical devices related to organ transplantation, metabolic, liver and kidney disease. The process has had the full support and backing IDIBAPS, the institution where the research and intellectual property of the project have been made. In addition, it has had the involvement of Mr. Ignasi Heras innovation expert and business development. Photo (left to right): Mr. Ignasi Heras, Dr. Ramon Gomis (IDIBAPS director), Dr. Carmen Peralta, Dr. Josep Lluís Falcó, Dr.Jordi Gracia and Dr. Anna Novials.
February 19, 2014
The Systemic Autoimmune Diseases research group of IDIBAPS coleads PRECISESADS, an European project to reclassify autoimmune diseases
The Systemic Autoimmune Diseases research group of IDIBAPS lead by Dr. Ricard Cervera coleads the clinical aspect of the European project PRECISESADS, which is planned 5-year study in 2.000 patients with various diseases: systemic lupus erythematosus, systemic sclerosis, Sjogren's syndrome, antiphospholipid syndrome or mixed connective tissue disease. These diseases currently are diagnosed based on clinical criteria relatively nonspecific often do not allow early diagnosis and, moreover, dealt mainly with anti-inflammatory drugs and immunosuppressants also nonspecific . The detection of new biomarkers should facilitate speed diagnosis and help in making therapeutic decisions.
February 18, 2014
Dr. Jordi Bruix received the prestigious Golden Award Medal of the Canadian Association for the Study of the Liver
Dr. Jordi Bruix , Hepatology Senior Consultant, Head of Oncology Liver Unit of Hospital Clínic de Barcelona, Head of Hepatic Oncology team at August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and Deputy Scientific at Networked Biomedical Research Center Hepatic and Digestive Diseases (CIBEREHD), received last February 9 the prestigious Golden Medal Award from the Canadian Association for the Study of the Liver, granted recognition for significant contributions to advances in the field of hepatology, especially liver cancer. Dr. Bruix received this award in the context of the Canadian Digestive Disease Week held in Toronto, where he gave his lecture Hepatocellular carcinoma. Past, present and future.
February 11, 2014
It is the first time described in vivo (in animals) oncogenic factor SOX11 protein, a transcription factor involved in the development and aggressiveness of lymphoma mantle cell, one of the most aggressive non-Hodkings lymphomas are. Because it is very difficult to treat, the research community is particularly interested in identifying therapeutic targets to address a disease whose survival does not exceed 3-5 years. This is the case of Dr. Virginia Amador, researcher in the area of human and experimental functional oncomorphology IDIBAPS, submitted last February 6 the results of their research work focused on the molecule SOX11. Under the title of the seminar Functional analysis of SOX11 in mantle cell lymphoma, Virginia showed that overexpression of the transcription factor SOX11 not only promotes the creation and progression of mantle cell lymphoma, but is also involved in the aggressiveness of it. This makes it the perfect therapeutic target to inhibit cancer development. The results are published by the journal Blood.
February 3, 2014
What happens in the brain when you briefly see something, for example a phone number on TV, and you try to remember it shortly afterwards? How does our brain manage this information? This question represents one of the most important challenges in the field of Neuroscience. It is believed that short-term memory largely determines our cognitive ability, including how we process information from the environment, or how we do mathematical calculations. Indeed, people with higher working memory capacity get better scores on intelligence tests, which suggests it is related to general cognitive abilities. So far it is known that the prefrontal cortex plays an important role in short-term memory and that people with mental disorders such as schizophrenia, depression, or dementia are impaired in this respect.